Back to News
Market Impact: 0.2
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
Source: GlobeNewswire
Healthcare & Biotech
The study remains on track to begin dosing by early November 2026. Topline Phase 1 proof-of-mechanism data are anticipated approximately six months after study initiation; no efficacy results were reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
- BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
- Why is NeoGenomics stock sliding today?
- Up 57% since June: this AI-picked pharma stock keeps climbing
- These stocks could benefit from a midterm election shake-up, JPMorgan says
- Vaxcyte shares surge on late-stage vaccine trial success